NMD4C Basic Science Trainee Committee Provides Leadership Opportunity for Next Generation of Neuromuscular Researchers

The NMD4C is excited to announce the nine members of the newly-formed Basic Science Trainee Committee! Representing the interests of trainees within the network, the BSTC offers an opportunity for professional growth for future leaders in neuromuscular research.

Committee Chair Dr Jean-Philippe Leduc-Gaudet shares “The formation of the Basic Science Trainee Committee is an exciting milestone for the NMD4C, providing important leadership opportunities for the next generation of neuromuscular researchers and strengthening the trainee voice within the network’s pre-clinical science activities. I look forward to working with this talented group of trainees to make a lasting impact in the Canadian neuromuscular research community.”

The group will work to communicate the training and professional development needs of trainees to the NMD4C pre-clinical science pillar leads, provide feedback, and suggest improvements to existing NMD4C trainee opportunities. Additionally, the BSTC will work on their own projects to strengthen the collaborative landscape of basic neuromuscular research resources in Canada, including:

  • Creating an open-source database of research protocols and expertise from neuromuscular research labs in Canada.
  • Implementing individual traineeships to learn specialized techniques.
  • Supporting the organization of events, workshops, and activities geared towards trainees that promote professional and personal development.

The BSTC is composed of 9 members, including a chair, co-chair, secretary, and general members, reflective of the diversity of the neuromuscular trainee population in Canada

Meet the Team:

  • Dr Jean-Philippe Leduc-Gaudet, Chair
  • Dr Emma Sutton, Co-Chair
  • Dr Adrien Rihoux, Secretary
  • Shatha Atieh
  • Jaryeon Lee
  • Dr Sean Ng
  • Dr Matthew Triolo
  • Rebecca Yaworski

Read more about the team and their mandate.

 

Meet the Basic Science Trainee Committee

Read next...

06 - 2026 Basic Research Summer School - EN

NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!

From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages. 

New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada

We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.

Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy

Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy

NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.